Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients

Clinical Infectious Diseases

Volumn 57, Issue 10, 2013, Pages 1504-1506

  Sheng, Wang Huei ^a   Chuang, Yu Chung ^a   Sun, Hsin Yun ^a   Tsai, Mao Song ^a   Chang, Sui Yuan ^a,b   Hung, Chien Ching ^a,c,d   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; TENOFOVIR;

HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MIXED INFECTION; PRIORITY JOURNAL; SYPHILIS;

ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; HEPATITIS B; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LAMIVUDINE;

EID: 84887931922     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit511     Document Type: Letter

References (10)

1. Kourtis AP, Bulterys M, Hu D.J., et al HIV-HBV coinfection - a global challenge. N Engl J Med 2012; 366: 1749-52.
2. Thio CL, Seaberg EC, Skolasky R.L., et al HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 1921-6.
3. Gatanaga H, Hayashida T, Tanuma J., Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis 2013; 56: 1812-9.
4. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2005; 2: 50-7.
5. Koike K, Kikuchi Y, Kato M., et al Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 2008; 38: 310-4.
6. Sun HY, Ko WC, Tsai J.J., et al Seropreva-lence of chronic hepatitis B virus infection among Taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol 2009; 104: 877-84.
7. Sheng WH, Kao JH, Chen P.J., et al Evolution of hepatitis B serological markers in HIV-Infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 1221-9.
8. Lin CF, Twu SJ, Chen P.H., Cheng JS, Wang JD Prevalence and determinants of hepatitis B antigenemia in 15007 inmates in Taiwan. J Epidemiol 2010; 20: 231-6.
9. Kabaçam G., Onder FO, Yakut M, et al Entecavir treatment of chronic hepatitis D. Clin Infect Dis 2012; 55: 645-50.
10. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305: 1432-40.